Increase in imported mupirocin-resistant Staphylococcus aureus from the tropics and subtropics: trends in Berlin from 2018 to 2025
Mupirocin resistance in Staphylococcus (S.) aureus (Mup-RSA) is emerging and may lead to S. aureus decolonisation failure. Our aim was to assess temporal trends in mupirocin-resistant S. aureus (Mup-RSA) and methicillin-resistant S. aureus (MRSA) among S. aureus –positive patients presenting to the Tropical Medicine outpatient Department, also including the Dermatology Department and the overall university hospital for context. We calculated annual percentages of Mup-RSA and MRSA among S. aureus –positive patients and modelled temporal trends using Poisson or negative binomial regression, estimating incidence rate ratios (IRR). From January 1, 2018, to June 30, 2025, Mup-RSA was detected in 3.1% (24/782) of patients with S. aureus at the Tropical Medicine Department, 1.1% (23/2030) at the Dermatology, and 0.5% (142/28,122) at the hospital overall. The rate of Mup-RSA among S. aureus -positive patients increased over time at the Tropical Medicine (IRR, 1.64; 95% CI, 1.3 – 2.06, p < 0.01 ), and at the Dermatology (IRR, 1.37; 95% CI, 1.12 – 1.67, p <0.01 ), but not at the hospital overall. MRSA did not increase significantly over time in either setting. MRSA in Mup-RSA was found in 4.2% (1/24), 4.3% (1/23), and 22.5% (32/142), respectively. Mup-RSA proportions are low overall, but have increased substantially in Tropical Medicine, with modest increases in Dermatology. Clinicians should be aware of both the emergence of Mup-RSA and the availability of alternative topical agents for decolonisation, particularly in contexts where S. aureus could be imported from regions with high Mup-RSA prevalence. • Mupirocin-resistant Staphylococcus aureus is emerging in tropical medicine outpatients • Imported cases in Berlin identified since 2020; mainly after travel to Southeast Asia • Among S. aureus -positive patients, resistance rates highest (9.2%) in first half of 2025 • Smaller increases in Dermatology Department; overall hospital rates stayed stable • Consider mupirocin susceptibility testing, esp. after travel or decolonisation failure
Authors
- Frank P. Mockenhaupt (ORCID: https://orcid.org/0000-0002-8117-5421)
- Daniel Humme
- Andreas K. Lindner (ORCID: https://orcid.org/0000-0001-5768-5109)
- Philipp Zanger (ORCID: https://orcid.org/0000-0001-6193-1966)
- Franziska Layer (ORCID: https://orcid.org/0000-0002-4613-6478)
- Dennis Nurjadi (ORCID: https://orcid.org/0000-0002-1278-5939)
- Leif G. Hanitsch (ORCID: https://orcid.org/0000-0002-8181-0093)
- Amy Stein
- Beate Kampmann (ORCID: https://orcid.org/0000-0002-6546-4709)
- Rasmus Leistner (ORCID: https://orcid.org/0000-0002-1225-9023)
- Paul Pitzinger (ORCID: https://orcid.org/0000-0001-9688-1890)
- Miriam Songa Stegemann (ORCID: https://orcid.org/0000-0002-7968-0429)
- Renate Krüger (ORCID: https://orcid.org/0000-0001-8728-9385)
- Josef G. Sägmüller
- Andreas Knaust
- Jessica L. Rohmann
- Maria Cristina Moreno-del Castillo
- Alice Hucko
Institutions
- Heidelberg University (DE)
- Robert Koch Institute (DE)
- University Hospital Heidelberg (DE)
- Vivantes Klinikum (DE)
- German Center for Infection Research (DE)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- New Microbes and New Infections
- Published
- 2026-03-01
- DOI
- https://doi.org/10.1016/j.nmni.2026.101740
- Primary Topic
- Antimicrobial Resistance in Staphylococcus
- Type
- article
- Field-Weighted Citation Impact
- 0.00